Harvard Bioscience Q3 2026 Results: Net Loss of $2.62M, Loss Widens
Harvard Bioscience reported revenues of $22.2 million for Q3 2026, a slight increase from $20.6 million in the prior year, though the company recorded a net loss of $2.6 million. For the nine months ended September 30, 2026, the net loss was $9.0 million compared to a $53.9 million loss in 2025, which had been driven by a significant $48.0 million goodwill impairment charge.
- Key figure
- Net loss $2.62M